Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.

Přehled studie

Detailní popis

This study is the first-in-human (FIH) trial of QLS2406-1 injection, a randomized, double-blind, placebo-controlled Phase I clinical study consisting of two parts.

Part A is a single ascending dose (SAD) design with doses escalated sequentially per the predefined escalation scheme. Eight overweight or obese participants will be enrolled in each cohort and randomized at a 6:2 ratio to receive QLS2406-1 or placebo. Part B is a multiple ascending dose (MAD) study in obese participants. Two dosing frequencies are to be explored: once weekly (QW), and once every two weeks (Q2W). For the QW schedule, 15 obese participants will be randomized at a 12:3 ratio to receive QLS2406-1 or placebo. For the Q2W schedule, 12 participants will be randomized at a 10:2 ratio to receive QLS2406-1 or placebo.

The primary objective is to evaluate the safety and tolerability of this new long-acting quad-agonist QLS2406-1. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate if the long-acting four-receptor agonist has possible pharmacodynamic effects measured as changes in weight, waist circumference and lipid profiles.

Typ studie

Intervenční

Zápis (Odhadovaný)

124

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 55 let (Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Part A

    1. Aged 18 to 55 years (inclusive) at screening, with no restriction on gender;
    2. At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and BMI ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive);
    3. Subjects are in good health as comprehensively assessed by the Investigator, with no clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasonography, clinical laboratory tests, etc.;
    4. Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy.
    5. Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written informed consent
  • Part B

    1. Aged 18 to 65 years (inclusive) at screening, regardless of gender;
    2. BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive);
    3. Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy;
    4. Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent;
    5. Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported).

Exclusion Criteria:

  1. Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications;

  2. History of any severe clinical disease, or clinically significant cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or malignancy within 24 weeks prior to randomization;

  3. Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc.;

  4. Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study;

  5. Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology;

  6. History of hypoglycemia within 24 weeks prior to randomization;

  7. 12-lead ECG at screening with heart rate >100 bpm or <50 bpm, second- or third-degree atrioventricular block, prolonged QTcF (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome;

  8. History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg;

  9. Use of any drugs, products or non-pharmacologic therapies (other than investigational product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening;

  10. Any screening laboratory value meeting any of the following criteria, including but not limited to:

    • Serum amylase or serum lipase >1.5 × upper limit of normal (ULN);
    • Fasting glucose abnormality or glycated hemoglobin (HbA1c) ≥6.5%;
    • Calcitonin >20 ng/L;
    • TG ≥5.65 mmol/L (500 mg/dL);
    • E value ≥12.0 kPa (FibroScan) (Part B only)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Part A Cohort 1

SAD dose 1

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part A Cohort 2

SAD dose 2

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part A Cohort 3

SAD dose 3

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part A Cohort 4

SAD dose 4

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part A Cohort 5

SAD dose 5

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 1

MAD dose 1

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 2

MAD dose 2

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 3

MAD dose 3

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 4

MAD dose 4

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 5

MAD dose 5

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Experimentální: Part B Cohort 6

MAD dose 6

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adverse Events (AEs)
Časové okno: Baseline to Day 71

A summary of AEs, SAEs, and other non-serious adverse events following single subcutaneous injection of QLS2406-1

Baseline to Day 71

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cmax of QLS2406-1
Časové okno: From baseline to the end of treatment (up to Day 71)

Maximum observed plasma concentration of QLS2406-1

From baseline to the end of treatment (up to Day 71)
AUC of QLS2406-1
Časové okno: From baseline to the end of treatment (up to Day 71)

Area under the serum concentration-time curve (AUC)

From baseline to the end of treatment (up to Day 71)
Tmax of QLS2406-1
Časové okno: From baseline to the end of treatment (up to Day 71)

Evaluate the time to reach peak plasma concentration of QLS2406-1

From baseline to the end of treatment (up to Day 71)
Half-life of QLS2406-1
Časové okno: From baseline to the end of treatment (up to Day 71)

Evaluate the time required for the plasma concentration of QLS2406-1 to decrease by 50%

From baseline to the end of treatment (up to Day 71)
% Change From Baseline in Body Weight
Časové okno: From baseline to the end of treatment (up to Day 71)

Weight

From baseline to the end of treatment (up to Day 71)
% Change From Baseline in Fasting Lipid Concentration
Časové okno: From baseline to the end of treatment (up to Day 71)

Fasting lipid concentration

From baseline to the end of treatment (up to Day 71)
Incidence of Anti-drug Antibodies (ADA)
Časové okno: From baseline to the end of treatment (up to Day 71)

Assessment of the incidence of anti-drug antibodies (ADA) developed against QLS2406-1 after dosing

From baseline to the end of treatment (up to Day 71)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

20. listopadu 2026

Primární dokončení (Odhadovaný)

30. srpna 2027

Dokončení studie (Odhadovaný)

30. března 2028

Termíny zápisu do studia

První předloženo

9. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

9. listopadu 2026

První zveřejněno (Aktuální)

16. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit